Natick, Massachusetts - Mercy BioAnalytics, Inc., a leading biotechnology research company focused on early cancer detection, announced that it has successfully raised $41 million in a Series A funding round. The funding round was led by Hatteras Venture Partners and included participation from iSelect Fund, Sozo Ventures, Broadway Angels, BrightEdge - American Cancer Society, and Novalis LifeSciences LLC.

Mercy BioAnalytics is dedicated to saving lives and relieving suffering across the globe by developing cutting-edge technologies for the early detection of cancer. The company is based in Natick, Massachusetts, and operates in the biotechnology research industry.

The funds raised in this round will be used to advance the development and commercialization of the company's proprietary liquid biopsy assay platform. This groundbreaking technology interrogates tumor-derived extracellular vesicles, which are abundant in blood and carry information about their cell of origin. By analyzing these vesicles, Mercy BioAnalytics' platform can detect cancer even at its earliest stages, enabling more effective treatment and improved patient outcomes.

"We are thrilled to have the support of such esteemed investors in our mission to revolutionize cancer detection and save lives worldwide," said Dawn Mattoon, Founder of Mercy BioAnalytics. "This funding will enable us to accelerate the development of our novel liquid biopsy assay platform and bring this life-saving technology to patients around the globe."